These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33444533)

  • 1. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
    Tseng CH; Hsu YC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87-88. PubMed ID: 33444533
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
    Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
    Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
    Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
    Choi WM; Choi J; Wong GL; Han S; Lim YS
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
    Chiu SY; Chang KC; Hu TH; Chien RN
    Aliment Pharmacol Ther; 2021 May; 53(9):1042-1043. PubMed ID: 33831240
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    Papatheodoridis G; Sypsa V; Lampertico P
    J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
    Yip TC; Wong GL
    Aliment Pharmacol Ther; 2020 Jan; 51(2):315-316. PubMed ID: 31880016
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Lee HA; Seo YS; Kim SU
    Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178
    [No Abstract]   [Full Text] [Related]  

  • 10. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
    Kamal F; Khan MA
    Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
    Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
    Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
    Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
    Lampertico P; Papatheodoridis GV
    Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
    Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
    BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
    Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply.
    Choi J; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jun; 5(6):916-917. PubMed ID: 31021372
    [No Abstract]   [Full Text] [Related]  

  • 19. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.